FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

OMB APPROVAL									
OMB Number:	3235-0287								
Estimated average burden									
hours per response	. 0.5								

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

1. Name and Address of Reporting Person* WAGNER CHARLES F JR				2. Issuer Name and Ticker or Trading Symbol VERTEX PHARMACEUTICALS INC / MA [VRTX]							(Che	ck all app	ship of Reporting Papplicable) irector ifficer (give title		rson(s) to Is 10% Ov Other (s	vner			
(Last)	c) (First) (Middle) VERTEX PHARMACEUTICALS				3. Date of Earliest Transaction (Month/Day/Year) 06/03/2024							-	below	below) EVP & Chief F		below)	·		
INCORPORATED 50 NORTHERN AVENUE				4. If Amendment, Date of Original Filed (Month/Day/Year)						Line)	 Individual or Joint/Group Filing (Check Applica Line) Form filed by One Reporting Person 								
(Street)	Street) BOSTON MA 02210				Dul	Dula 10h5 1(a) Transaction Indication								Form filed by More than One Reporting Person					
(City)	(Sta	ate) (Z	Zip)		Rule 10b5-1(c) Transaction Indication Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan that is intensatisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.								nded to						
		Table	I - Non	-Deriva	tive S	Secu	rities	s Acq	uired,	Dis	posed of	, or E	Bene	ficial	y Own	ed			
1. Title of Security (Instr. 3) 2. Transac Date (Month/Da				Execut ly/Year) if any		Deemed ution Date, / th/Day/Year)		3. Transaction Code (Instr. 8) 4. Securities Acquired (Disposed Of (D) (Instr. 3) 5)				Securit Benefic Owned	Amount of curities neficially vned Following		n: Direct or Indirect nstr. 4)	7. Nature of Indirect Beneficial Ownership			
								Code	v	Amount	(A) or (D) Pr		rice	Reported Transaction(s) (Instr. 3 and 4)				(Instr. 4)	
Common Stock 06/03/2					2024			S ⁽¹⁾		3,250	D \$4		\$460	0 47,137			D		
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)																			
1. Title of Derivative Security (Instr. 3)	ative Conversion Date Execution Date, rity or Exercise (Month/Day/Year) if any			4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		te	7. Title and Amount of Securities Underlying Derivative Security (Ins 3 and 4)		D Se (Ii	Price of erivative ecurity nstr. 5)	tive derivative by Securities		10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)	
					Code	v	(A)	(D)	Date Exercisable		Expiration Date	Title	Amount or Number of Shares						

Explanation of Responses:

1. Transaction made pursuant to Mr. Wagner's company approved trading plan under Rule 10b5-1, which was entered into on 02/26/2024.

Remarks:

/s/ Christiana Stevenson, Attorney-in-Fact

06/05/2024

** Signature of Reporting Person Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

- * If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.